

In the claims:

1-29. **(Cancelled)**

30. **(Previously presented)** A method of stimulating a multi-epitopic immune response to a tumor-associated antigen comprising

administering to a host a ~~soluble~~-complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein the ~~soluble~~-complex induces host antibodies reactive with at least one other epitope of the tumor-associated antigen.

31-70. **(Cancelled)**

71. **(Previously presented)** The method of claim 30, wherein the antibody is selected from the group consisting of a monoclonal antibody, a single chain antibody, a humanized antibody, and a chimera antibody .

72-74. **(Cancelled)**

75. **(Currently amended)** The method of claim 74~~30~~, wherein the tumor-associated antigen is associated with a cancer ~~is~~-selected from the group consisting of breast, ovarian, prostate, and gastro-intestinal cancers.

76. **(Previously presented)** The method of claim 30, wherein the host is a human.

77-84. **(Cancelled)**

85. **(Currently amended)** A composition for altering immunogenicity of a tumor-associated antigen comprising a ~~soluble~~-complex of a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that specifically binds to an epitope of the antigen, wherein administration of the composition to a host results in a multi-epitopic immune response including

production of antibodies reactive with at least one other epitope associated with the tumor-associated antigen.

86. **(Previously presented)** The composition of claim 85, wherein the antibody is selected from the group consisting a monoclonal antibody, a single chain antibody, a humanized antibody, and a chimera antibody.

87. **(Previously presented)** The composition of claim 85, wherein the antibody is a monoclonal antibody.

88. **(Previously presented)** The composition of claim 87, wherein the monoclonal antibody is produced by the hybridoma having ATCC deposit number PTA-1883.

89. **(Previously presented)** The composition of claim 87, wherein the monoclonal antibody is produced by the hybridoma having ATCC deposit number PTA-975.

90-92. **(Cancelled)**

93. **(Currently amended)** The composition of claim ~~92~~85, wherein the tumor-associated antigen is associated with a cancer is selected from the group consisting of breast, ovarian, prostate, and gastro-intestinal cancers.

94. **(Cancelled)**

95. **(Currently amended)** The composition of claim 85, wherein the tumor-associated antigen is an antigen shed ~~soluble antigen~~ by tumors.

96. **(Previously presented)** The composition of claim 85, wherein the host is a human.

97. **(Cancelled)**

98. **(Previously presented)** The method of claim 30, wherein the antibody is a non-human antibody.

99. **(Currently amended)** The method of claim 30, wherein the ~~antibody or antigen binding~~ fragment thereof complex is administered with an adjuvant.

100. **(Currently amended)** The method of claim 30, wherein the antibody or antigen binding ~~fragment thereof~~ of the complex is formulated at a dose of from about 0.1 µg to about 2 mg per kilogram of body weight of the host.

101. **(Previously presented)** The method of claim 30, wherein tumor-associated antigen is an ovarian tumor-associated antigen.

102. **(Previously presented)** The method of claim 101, wherein the ovarian tumor-associated antigen is CA125.

103. **(Previously presented)** The method of claim 30, wherein the soluble complex induces cytotoxic T cells reactive with at least one other epitope of the antigen.

104. **(Currently amended)** A method of stimulating a multi-epitopic immune response to a tumor-associated antigen comprising administering to a host a ~~soluble complex formed from~~ an consisting essentially of a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein the ~~soluble~~ complex induces host antibodies and cytotoxic T cells reactive with at least one other epitope of the tumor-associated antigen.

105. **(Currently amended)** A method of stimulating a multi-epitopic immune response to a tumor-associated antigen comprising administering to a host a ~~soluble complex formed from~~ an consisting essentially of a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein the ~~soluble~~ complex induces cytotoxic T cells reactive with at least one other epitope of the tumor-associated antigen.

106. **(Currently amended)** The method of claim 105, wherein the soluble complex further induces host antibodies reactive with other epitopes of the tumor-associated antigen.

107. **(Currently amended)** A method of treating an oncological disease comprising administering to a host a ~~soluble~~-complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein the ~~soluble~~-complex induces host antibodies reactive with at least one other epitope of the tumor-associated antigen.

108. **(Currently amended)** The method of claim 107, wherein the ~~soluble~~-complex induces cytotoxic T cells reactive with other epitopes of the tumor-associated antigen.

109. **(Currently amended)** A method of treating an oncological disease comprising administering to a host a ~~soluble~~-complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein the ~~soluble~~-complex induces cytotoxic T cells reactive with at least one other epitope of the tumor-associated antigen.

110. **(Currently amended)** The method of claim 107, wherein the ~~soluble~~-complex induces host antibodies reactive with other epitopes of the antigen.

111. **(Currently amended)** The method of claim 30, wherein the antibody or antigen binding fragment thereof is formulated in the complex at a dose of about 2 mg per host.

112. **(Currently amended)** The method of claim 30, wherein the antibody or antigen binding fragment thereof is formulated in the complex at a dose of from about 0.1 µg to about 200 µg per kilogram of body weight of the host.

113. **(Previously presented)** The method of any of claims 30, 104, 105, 107, and 109, wherein the antibody is a non-human antibody.

114. **(Previously presented)** The composition of claim 85, wherein the antibody is a non-human antibody.

115. **(Currently amended)** The composition of claim 85, wherein the tumor-associated antigen is an ~~circulating soluble~~ antigen shed by tumors.